期刊文献+

硼替佐米或联合三氧化二砷诱导HL-60细胞凋亡实验研究 被引量:4

HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro
下载PDF
导出
摘要 目的探讨硼替佐米单独或联合三氧化二砷对HL-60细胞凋亡的影响。方法不同浓度硼替佐米、三氧化二砷处理细胞12~48h,采用MTT比色法检测细胞增殖活性;DNA凝胶电泳、细胞形态学观察、流式细胞仪检测细胞凋亡。结果10~50nmol/L硼替佐米可有效抑制HL-60细胞增殖,并诱导其发生凋亡。其中10nmol/L剂量处理12h,即有细胞凋亡发生,延长作用时间或增加药物剂量,细胞凋亡率明显增加。选择15μmol/L三氧化二砷与10nmol/L硼替佐米联合应用,可见HL-60细胞凋亡率比两种药物单独使用时显著增加。结论硼替佐米对HL-60细胞存在时间和剂量依赖性的细胞凋亡效应,与三氧化二砷联合具有明显的协同作用。 Objective To investigate the effect ofbortezomib alone and in combination with arsenic trioxide on apoptosis of HL-60 cells. Methods HL-60 cells were treated with bortezomib alone or in combination with arsenic trioxide for 12 to 48 h and the cell proliferation was analyzed with MTT assay, and cell apoptosis detected by DNA gel electrophoresis, fluorescence microscopy and flow cytometry. Results At the concentrations of 10 to 50 nmol/L, bortezomib effectively inhibited HL-60 cell proliferation, and induced cell apoptosis. A 12-hour bortezomib treatment at 10 nmol/L was sufficient to induce cell apoptosis, and prolonged treatment or increased concentration significantly increased HL-60 cell apoptotic rate, Combined treatment of the cells with bortezomib (10 nmol/L) and arsenic trioxide (15 μmol/L) resulted in an even higher cell apoptosis rate than that induced by the respective agent alone. Conclusion Bortezomib can induce HL-60 cell apoptosis in a time- and dose-dependent manner, and a synergistic effect can be observed of bortezomib and arsenic trioxide in apoptosis induction.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2007年第7期1022-1025,共4页 Journal of Southern Medical University
基金 广东省科技攻关项目(B30202)~~
关键词 硼替佐米 三氧化二砷 凋亡 bortezomib arsenic trioxide apoptosis
  • 相关文献

参考文献8

  • 1陆地,白晓春,桂莉,李明,曾位森,韩西群,罗深秋.三氧化二砷诱导人类恶性淋巴瘤细胞凋亡及机制探讨(英文)[J].第一军医大学学报,2003,23(10):997-1001. 被引量:9
  • 2斯佩克特 D L 戈德曼 R D 莱因万德 L A.细胞实验指南[M].北京:科学出版社,2001.685-687.
  • 3Voorhees PM,Dees EC,O'Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9(17):6316-25.
  • 4Gatto S,Scappini B,Pham L,et al.The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate[J].Haematologica,2003,88(8):853-63.
  • 5Horton TM,Gannavarapu A,Blaney SM,et al.Bortezomib interactions with chemotherapy agents in acute leukemia in vitro[J].Cancer Chemother Pharmacol,2006,58(1):13-23.
  • 6Dai Y,Rahmani M,Pei XY,et al.Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms[J].Blood,2004,104(2):509-18.
  • 7Dai Y,Rahmani M,Grant S,et al.Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappaB-dependent process[J].Oncogene,2003,22(46):7108-22.
  • 8Smolewski P,Duechler M,Linke A,et al.Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells[J].Leuk Res,2006,30(12):1521-9.

二级参考文献4

共引文献13

同被引文献28

  • 1刘琳,赵伟,秦叔逵,李苏宜,邱少敏,王南瑶,陈惠英.三氧化二砷抗裸鼠人结肠癌移植瘤作用及其机制的研究[J].中国肿瘤临床,2005,32(18):1067-1070. 被引量:10
  • 2孙启鑫,孟凡义,扶云碧,李利.硼替佐米单用或联合三尖杉酯碱体外诱导HL-60细胞凋亡实验研究[J].中国实验血液学杂志,2007,15(2):233-236. 被引量:15
  • 3Tactic R, Rosen F, Abramson I, et al. Use of nude mouse xenogratts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenogratts [ J ]. Cancer Treat Rep, 1987, 71 (3): 297-304.
  • 4Tan C, Waldmarm TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia [J]. Cancer Res, 2002, 62(4): 1083-6.
  • 5Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro [J]. Leukemia, 2004, 18(8): 1357-63.
  • 6Cortes J, Thomas D, Koller C, et al. Phase I study ofbortezomib in refi'actory or relapsed acute leukemias [J]. Clin Cancer Res, 2004, 10(10): 3371-6.
  • 7Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies [J]. Blood, 2005, 105(8): 3058-65.
  • 8Attar EC, De Angelo D J, Sirulnik A, et al. Addition of bortezomib (Velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate [J]. Blood, 2005, 106(11): 780a.
  • 9Mitchell B S. The proteasome-an emerging therapeutic target in cancer [ J ]. N Engl J Med, 2003,26,348 (26) : 2597-2598.
  • 10VoorheesPM, DeesEC, O'NeilB, et al.. Theproteasomeasa target for cancer therapy [J]. Clin Cancer Res,2003,9(17) :6316- 6325.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部